Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital

Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Breast cancer in women using digoxin: tumor characteristics and relapse risk

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Whole genome sequencing of breast cancer

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Subtypes in BRCA-mutated breast cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Kathrin Strasser-Weippl
  • Nora Horick
  • Ian E Smith
  • Joyce O'Shaughnessy
  • Bent Ejlertsen
  • Frances Boyle
  • Aman U Buzdar
  • Pierre Fumoleau
  • William Gradishar
  • Miguel Martin
  • Beverly Moy
  • Martine Piccart-Gebhart
  • Kathleen I Pritchard
  • Deborah Lindquist
  • Erica Rappold
  • Dianne M Finkelstein
  • Paul E Goss
Vis graf over relationer

INTRODUCTION: Worldwide, many patients with HER2+ (human epidermal growth factor receptor 2-positive) early breast cancer (BC) do not receive adjuvant trastuzumab. Hazards of recurrence of these patients with respect to hormone receptor status of the primary tumor have not been described.

METHODS: Using data from 1,260 patients randomized to placebo in the adjuvant TEACH trial, we report 10-year annual hazards of recurrence in HER2+ patients not treated with anti-HER2 therapy.

RESULTS: Disease-free survival (DFS) was 75% after 5 and 61% after 10 years, respectively. Patients with HER2+ hormone receptor-positive (HR+ (hormone receptor-positive); ER+ (estrogen receptor-positive) or PR+ (progesterone receptor-positive)) disease had a significantly better DFS than patients with HER2+ HR- (ER-/PR-) disease (hazard ratio 0.72, P=0.02). This difference was explainable by a significantly higher hazard of recurrence in years 1 to 5 in HER2+ HR- compared to HER2+ HR+ patients, with a mean risk of recurrence of 9%/year for HR- versus 5%/year in HR+ patients (hazard ratio 0.59, P=0.002 for years 1 to 5). The high early risk of recurrence of HER2+ HR- patients declined sharply over time, so that it was similar to that seen in HER2+ HR+ patients in years 6 to 10 (hazard ratio 0.97, P=0.92 for years 6 to 10).

CONCLUSIONS: Our results show that outcomes in HER2+ patients with early BC not receiving anti-HER2 therapy strongly depend on HR expression. The very high early risk of relapse seen in HER2+ HR- patients is particularly relevant in health care settings with limited access to adjuvant anti-HER2 treatment. The event rates shown for subpopulations of HER2+ BC patients suggest that in resource-constrained environments patients with HER2+ HR- early BC should be prioritized for consideration of adjuvant anti-HER2 therapy.

TidsskriftBreast Cancer Research Review
Sider (fra-til)17-56
Antal sider39
StatusUdgivet - 2015

ID: 45952065